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Health care spending in North America is consuming an ever-increasing share of Gross
Domestic Product (GDP). A large proportion of alternative health care is consumed in the
form of natural health products (NHPs). The question of whether or not NHPs may provide a
cost-effective choice in the treatment of disease is important for patients, physicians and policy
makers. The objective of this study was to conduct a systematic review of the literature in order
to find, appraise and summarize high-quality studies that explore the cost effectiveness of NHPs
as compared to conventional medicine. The following databases were searched independently in
duplicate from inception to January 1, 2006: EMBASE, MEDLINE, CINAHL, BioethicsLine,
Wilson General Science abstracts, EconLit, Cochrane Library, ABI/Inform and SciSearch.
To be included in the review, trials had to be randomized, assessed for some measure of cost
effectiveness and include the use of NHPs as defined by the Natural Health Products
Directorate. Studies dealing with diseases due to malnutrition were excluded from appraisal.
The pooled searches unveiled nine articles that fit the inclusion/exclusion criteria. The
conditions assessed by the studies included three on postoperative complications, two on
cardiovascular disease, two on gastrointestinal disorders, one on critically ill patients and one
on urinary tract infections. Heterogeneity between the studies was too great to allow for meta-
analysis of the results. The use of NHPs shows evidence of cost effectiveness in relation to
postoperative surgery but not with respect to the other conditions assessed. In conclusion,
NHPs may be of use in preventing complications associated with surgery. The cost effectiveness
of some NHPs is encouraging in certain areas but needs confirmation from further research.
Keywords: CAM–complementary and alternative medicine–cost effectiveness–natural health
products–NHPs
Introduction
Consumers in North America are increasingly spending
more on complementary and alternative medicine (CAM)
andnatural health products (NHPs). Thereare anumberof
studiesthathaveinvestigated thecosteffectiveness ofCAM
in terms of the different modalities that are usually
associated with CAM, such as acupuncture, Feldenkrais,
chiropractic and massage therapy as examples (1,2). In
reviewing the cost effectiveness of CAM, NHPs were often
also included. However, there are no studies that reviewed
the cost effectiveness of just NHPs specifically. With this
review we focused on the cost effectiveness of NHPs.
Healthcare Spending: Conventional
and Complementary
Health care spending in the US reached almost $2 trillion
[$2.6 trillion 2004 CAD (all currency conversion were
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trillion ($2.07 trillion 2000 CAD) in 2000. This represents
a $500 billion increase in just 4 years. In Canada, health
care spending reached $130 billion in that same year (4).
Prescription costs account for some of the highest rates
of increase in health care spending as evidenced by a
growth rate of 8.2% in drug costs in the US between
2003 and 2004 (3). In Canada, an estimated $18.0 billion
was spent on prescription of drugs in 2004 and $16.3
billion in 2003 representing an increase of 10.4% in 1
year (4).
Health care spending is increasing, both from a
government and a private standpoint. As people make
health care choices to empower themselves (5) and make
their own treatment choices, they are also seeking the
assistance of CAM practitioners. In a 2003 survey,
conducted by Statistics Canada, 12.4% of Canadians
over the age of 12 years indicated that they had contact
with alternative health care providers in the past 12
months (6). This was up from an estimated 7.6% in
1999(7). According to the 2003 survey, alternative health
care providers included: ‘massage therapists, acupunctur-
ists, homeopaths, naturopaths, Feldenkrais or Alexander
teachers, relaxation therapists, biofeedback teachers,
rolfers, herbalists, reflexologists, spiritual healers, reli-
gious healers, etc.’ (6). A 2002 US National Health
Interview Survey conducted by the Center for Disease
Control and Prevention’s National Center for Health
Statistics (NCHS) found that 62% of US adults had used
some form of CAM in the past 12 months (8).
Regarding the issue of cost, Eisenberg et al. (9)
conservatively estimated that the total annual out-of-
pocket spending, in the United States, on all comple-
mentary therapies was in the region of $27 billion USD
($37 billion 1997 CAD) in 1997. The estimated total out-
of-pocket spending by Canadians on CAM was $3.8
billion CAD in 1997 (10). An Australian 2000 survey
estimated that the annual expenditure on CAM was
$AU621 million ($536 million 2000 CAD) (11).
NHPs are defined by Health Canada’s Natural Health
Products Directorate (NHPD) as: vitamins and minerals,
herbal remedies, homeopathic medicines, traditional
medicines such as traditional Chinese medicines and
other products including probiotics, amino acids and
essential fatty acids. Recent regulations created by the
NHPD require that NHPs are safe for public consump-
tion as over-the-counter products, be available for self-
care and self-selection and not require a prescription to
be sold (12). These products are available and sold over
the counter in pharmacies, grocery stores and health food
stores. Consumers either self-select NHPs or may be
prescribed these products by naturopathic doctors,
chiropractors, herbalists and staff at health food stores.
In 1997, it was estimated that the gross income for the
NHP industry in Canada was between 1.5 and 2 billion
dollars and that the annual growth would be 10 to 15%
per annum (8). The estimated annual out of pocket
expenditures on NHPs in 2005 was 3.6 billion dollars
CAD (13).
The Nonprescription Drug Manufacturers Association
of Canada’s (NDMAC) Health Vision 1999/2000 pub-
lication on consumer attitudes and behaviors found that
in 1999, 26% of respondents had used herbal and/or
homeopathic remedies (14). This number had increased
to 41% by the year 2000 (14). A March 2005 survey of
Canadians by IPSOS Reid indicated that reported NHP
usage among Canadians is high, with seven out of ten
Canadians reporting that they have used a NHP (12). It
appears as if more and more Canadians are incorporating
NHPs into their health care choices.
This trend is not only evident in North America but is
also occurring in other countries. The 2000 Australian
survey estimated that annual expenditure on CAM was
$AU1671 million ($1.442 million 2000 CAD) (11). This
represents a 120% increase since 1993, a time during
which inflation in Australia increased by an average of
3.2% per annum (11).
Who is Using NHPs?
The IPSOS Reid survey indicates that NHP users were,
by far, more women than men, likely to be better
educated and a have higher household income (12). This
demographic is consistent with the demographics that
were found in the Australian survey on alternative
medicine (11).
The desire of Canadians to empower themselves in their
health care choices is evident in the reasons why they
choose NHPs. In the IPSOS Reid survey, 52% indicated
that they chose an NHP because of the desire to control
or influence their personal health (12). A further 21% did
so to help maintain and promote their health and prevent
illness (12).
Economic Evaluation
Economic evaluation is the systematic appraisal of costs
and benefits of projects, or alternative ways of achieving
the same outcomes, undertaken to determine the eco-
nomic effectiveness of the alternatives (1,15). There are a
number of different methods employed in an economic
evaluation, each with its own purpose for the analysis.
The information for this section was obtained in part
from the National Information Center on Health Services
Research and Health Care Technology’s (NICHSR)
Health Economics Information Resources program
developed by Moira Napper and Jean Newland (15).
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‘A CBA is an economic evaluation in which all costs and
consequences of a program are expressed in the same
units, usually money. CBA is used to determine allocative
efficiency; i.e., comparison of costs and benefits across
programs serving different patient groups. Even if some
items of resource or benefit cannot be measured in the
common unit of account; i.e., money, they should not be
excluded from the analysis’ (15). Herman (1) identifies
the challenge of CBA in that its analysis requires putting
a monetary value on all health outcomes and ultimately
on life. There is inherent difficulty with this type of
analysis and as a result very few true CBAs have yet been
performed (15).
Cost-Effectiveness Analysis (CEA)
‘A CEA is an economic evaluation in which the costs and
consequences of alternative interventions are expressed as
costs per unit of health outcome. CEA is used to
determine technical efficiency; i.e., comparison of costs
and consequences of competing interventions for a given
patient group within a given budget’ (15). The result will
be a comparison of cost per unit of improvement between
examined treatments (15). Comparison of multiple out-
comes is not possible with this type of analysis (1);
however, the analysis does help answer urgent questions,
such as how much it would cost to reduce hip fractures in
osteoporotic women (1).
Cost-Minimization Analysis (CMA)
‘A CMA is an economic evaluation in which conse-
quences of competing interventions are the same and in
which only inputs, that is, costs are taken into
consideration. The aim is to decide the least costly way
of achieving the same outcome’ (15).
Cost-Utility Analysis (CUA)
‘A CUA is a form of economic study design in which
interventions which produce different consequences, in
terms of both quantity and quality of life, are expressed
as ‘‘utilities’’. These are measures that comprise both
length of life and subjective levels of wellbeing. The best-
known utility measure is the ‘‘quality adjusted life year’’
or QALY. In this case, competing interventions are
compared in terms of cost per utility (cost per QALY)’
(15). Health outcomes are assigned a value based on their
contribution to quality of life (1). Since CUA analysis
provides for summary measures of quality of life, short-
term changes, such as those in acute situations, and
discrete changes, such as blood pressure control, are not
easily identifiable (1).
Perspective of the Economic Analysis
Regardless of the type of analysis performed, the
perspective of the economic analysis is another con-
sideration. Is the perspective that of the patient,
insurance company or health care system? Determination
of the perspective will determine what costs are collected
and measured in the analysis.
Classification of Outcomes—ECHO Model
Another component of economic evaluation involves the
classification of the outcomes that are assessed. Gunter
(16) puts forth the point of view that ‘It is essential to
measure a balance of outcomes, in the analysis, to ensure
that no one outcome is being maximized to the detriment
of another.’ Kozma et al. (17) put forth the Economic,
Clinical and Humanistic Outcomes (ECHO) model which
recognizes that the outcome of medical care would be
along three dimensions—economic, clinical and human-
istic outcomes. Outcomes that occur as a result of disease
or treatment are classified as clinical outcomes. Direct,
indirect and intangible costs are considered economic
outcomes and consequences of disease or treatment on
patient functional status or quality of life are considered
as humanistic outcomes (17).
In this review, we have systematically searched the
literature for randomized clinical trials (RCTs) that
collected data regarding the cost effectiveness of NHPs
in comparison to conventional therapies. Our review is
limited to RCTs as they provide the highest-level
evidence with the least bias, an issue with special
relevance in the study of evidence on CAM wherein
different therapies are often combined. Such combina-
tions make it very difficult to ascertain both quality of
evidence and causality due to any single treatment
component (i.e. NHP). Findings of this review should
be of interest to the public, health care professionals and
policy makers involved in health care.
Data Sources
The following databases were searched independently
by D.A.K. and J.H. in duplicate from inception to
January 1, 2006: EMBASE, MEDLINE, CINAHL,
BioethicsLine, Wilson General Science abstracts,
EconLit, Cochrane Library, ABI/Inform and SciSearch.
Review Methods
To be included in the review, trials had to be
randomized, assessed for some measure of cost evalua-
tion (either CBA, CEA, CMA or CUA) and include the
use of a NHP as defined by the NHPD. Manuscripts
dealing with conditions of disease solely due to malnutri-
tion were excluded from appraisal, since supplementation
eCAM 2009;6(3) 299of a frank nutritional deficiency would clearly be cost-
effective. Where necessary, authors were contacted for
clarification of evidence.
Data extraction sheets were used to collect and compile
data on each of the articles included in the review. The
extraction sheets were completed independently by
D.A.K. and J.H. Primary data points collected included:
type of study, costs (direct and indirect), intervention,
outcomes measured, adverse effects, type of economic
analysis and the principal economic characteristics
associated with each study (including the timing of
analysis), level of costs analyzed and economic evaluation
based on the ECHO model described above.
Results
The pooled searches unveiled 585 original articles. Of
these, eight fit our inclusion/exclusion criteria. One
additional study was found through hand-searching the
bibliographies of relevant manuscripts. The search
process is further detailed in Fig.1. Conditions assessed
by the studies included three on postoperative complica-
tions (18–20), two on cardiovascular disease (21,22),
two on gastrointestinal disorders (23,24), one on critically
ill patients (25) and one on urinary tract infections
(UTIs) (26).
The results of the analysis revealed that eight of the
nine studies demonstrated that when an NHP was
included in care, there was a concomitant cost savings
with the positive health outcomes demonstrated.
Cost savings in the studies ranged from 3.7 to 73%
reduction in costs over the control group. A summary
of the studies included in this analysis is presented in
Table1.
NHPs Found to be Cost-Effective
The three studies related to enriched perioperative nutri-
tion and enriched enteral nutrition for the critically ill
demonstrated a reduction in postoperative complications
and mortality and therefore an overall reduction in
hospital-related costs. The two cardiovascular studies
showed that while supplementation with NHPs, in this
case Vitamin E and n-3 polyunsaturated fatty acids
(n-3 PUFA), did improve clinical outcome, costs were
not necessarily reduced. The Davey et al. (21) study showed
that Vitamin E supplementation was cost-effective as
compared with control by an average of $578 USD in
improving outcomes post MI (20). However, the Franzosi
et al. (22) study demonstrated that supplementation with
n-3 PUFA’s while significantly decreasing negative out-
comes post MI, did so with only with an increase in costs
(21). The cost increase of $1030 USD was solely attributed
to the cost of the n-3 PUFA supplementation. Regarding
the use of NHPs to treat gastrointestinal disorders and
UTIs, typically outpatient conditions, the studies demon-
strated that NHPs did provide cost savings (ranging from
19 to 73%). Adverse effects were reported but were not
quantified in monetary terms, nor taken into consideration
in the cost effectiveness analysis.
585 articles found through
systematic searches
60 abstracts screened for
inclusion
525 rejected outright
52 articles rejected, as they did
not fit the inclusion criteria
8 articles retrieved for full
analysis
15 articles excluded
4 looked at diet or dietary counseling  
4 included no analysis of costs 
2 looked at parenteral therapies 
2 were retrospective  
1 lacked randomization 
1 only included data on hypothetical costs  
1 provided inadequate description of the 
intervention 
9 articles included in
systematic review
16 additional articles
retrieved from hand-
searching review articles
Figure1. Flow chart of studies excluded and selected for systematic review.
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eCAM 2009;6(3) 301Comparison of Costs Included in the Studies
A summary of the economic characteristics of each study
is presented in Table2. There were a number of different
methods used to derive the costs. In some studies, the
actual costs were collected as the data was being
collected. Other studies used surrogate measures for
cost such as third party payer reimbursements rates at
the Diagnosis Related Group (DRG) level. In other
studies, the costs were estimated through consultation
with medical experts regarding the components of care
that would have been required for the usual care of a
patient with a given health condition.
The level of the cost analysis is an important
consideration since this determines what costs will be
collected and included in the analysis. For example,
studies that collected cost data at the level of the
individual took into consideration: the costs of days of
lost work, transportation costs to and from appointments
and other identifiable direct and indirect patient costs.
There were a number of studies that looked at the costs
from the perspective of the hospital, for example,
collecting data for medical or nursing care and also
costs while in the intensive care unit. These studies did
not incorporate costs at the individual patient level.
A number of studies were done from the perspective of a
national health service, which for outpatient conditions
provides for a broader, more policy-based collection of
costs; i.e. physician consultations, drugs utilized and
diagnostic procedures performed.
Discussion
There is a range of different conditions that are included
in our analysis. Some of the conditions that were
analyzed are those that are usually treated as outpatient
conditions (i.e. dyspepsia, constipation and UTIs), while
others relate to reducing complications and hospital care
after a nonfatal cardiac event. The studies that were
included demonstrate that NHPs do provide a reduction
in overall costs for each of the conditions that assessed
except for the one study on cardiovascular health (22).
A glance at Table2 reveals that there is little
consistency across the studies that we found regarding
economic characteristics. Further, in the evaluation of
cost effectiveness of different treatment options, within
the health care area, there are as yet, no consistent
standards that are employed and a number of issues that
still need resolution (27). Direct costs are those costs that
can be attributed directly to the patient. For example,
most of the studies incorporated direct hospital costs in
their analysis, whereas one study by Franzosi et al. (22)
looked at only the incremental direct costs, i.e. costs that
were incurred for a patient beyond what was provided, as
a baseline, for all patients in the study (21).
Limitations
A principal limitation to this systematic review is the
paucity and variability of the data we were able to find.
Given the number of studies, the different NHPs studied,
and the variation in conditions of disease, it is impossible
to combine our findings statistically in a meta-analysis.
This limitation may have been partially alleviated by
allowing the inclusion of observational studies, however,
this would have come at the cost of reducing the validity
of our findings overall.
There is limited evidence regarding the cost effective-
ness of NHPs overall both in terms of the numbers of
studies that have been conducted and the rigor of the
methodologies employed. This may be partially due to
the limited research focus on NHPs specifically and also
on cost effectiveness studies in general. The inclusion of
data points required for a robust cost effectiveness model
is required at the design phase of a trial. Considering the
lack of use of NHPs in conventional health care, it is no
surprise that cost effectiveness issues, of great importance
to policy makers, are not standard components of trials
that use NHPs. Efficacy and adverse effects are the
principal concerns for these types of intervention and as
such the issue of cost effectiveness is probably often not
considered, especially at the outset.
Economic Evaluation
Economic evaluation and analysis is not new. Analysis of
the costs and benefits of alternatives have been performed
in the industrial arena for a long time. However, the
inclusion of economic evaluation within the health care
sector is a relatively new phenomenon in a time where
health care costs are ever increasing and administrators
are faced with having to do more with less. Table2
highlights the difficulty that exists due to a lack of
standardization in the performance of economic evalua-
tions thus making the comparison of the economic results
from one study to the next difficult at best.
NHPs are purported to have fewer side-effects than
other medical therapies. Therefore, the incorporation of
the humanistic outcomes in the cost effectiveness analysis
is particularly important for NHPs. Few studies exam-
ined the humanistic dimension and therefore some of the
potential benefits of NHPs may have been excluded from
analysis. These potential benefits could include improve-
ments in quality of life and reductions in drug-induced
side-effects that certainly have an economic impact.
If these humanistic elements were to be included, it is
conceivable that the cost benefits would be greater than
reported for these studies regarding NHPs. Possible
indirect cost benefits that could arise include a speedier
recovery leading to earlier return to employment and
changes in dietary habits leading to reduced health care
costs in the future. The placebo effect, however, does
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eCAM 2009;6(3) 303provide genuine relief to patients and if improved by the
use of natural therapies like NHPs, should not be
discounted out of hand.
Finally, the preponderance of studies that we found
relating to the use of NHPs for postsurgical care with a
cost effectiveness component implies that this is an area
of real importance with regards to cost savings. It is also
indicative of the potential for NHPs to provide benefit in
this context. Our findings support this potential and raise
the issue of whether policy changes with regards to the
inclusion of certain NHPs in postoperative care would
not in fact ameliorate conditions for patients, public
health care and third-party insurers.
Conclusion
The use of NHPs demonstrated some evidence of cost
effectiveness in relation to postoperative surgery, yet is
inconclusive in relation to the other conditions assessed.
Further clinical research in the postsurgical setting is
needed to clearly establish the cost benefits that may be
achievable in this and other settings. Another aspect
highlighted by this review is the lack of consistency
regarding the cost effectiveness analysis. Further work
needs to be done to determine a cost effectiveness
framework which incorporates humanistic outcomes
within which to evaluate NHPs.
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